<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970967</url>
  </required_header>
  <id_info>
    <org_study_id>CTP-BRST-01</org_study_id>
    <nct_id>NCT03970967</nct_id>
  </id_info>
  <brief_title>Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases</brief_title>
  <official_title>A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpha Tau Medical LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpha Tau Medical LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A unique approach for cancer treatment employing intratumoral diffusing alpha radiation&#xD;
      emitter device for newly Diagnosed Breast Carcinoma patients with distant metastases&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, open label, single arm, controlled study, assessing the safety&#xD;
      and efficacy of diffusing alpha emitters radiation therapy (DaRT) delivered through&#xD;
      radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]&#xD;
      inserted into malignant breast lesions.&#xD;
&#xD;
      This approach combines the advantages of local intratumoral irradiation of the tumor, as used&#xD;
      in conventional brachytherapy, with the power of the alpha radiation emitting atoms, that&#xD;
      will be introduced in quantities considerably lower than radiation therapy already used in&#xD;
      patients.&#xD;
&#xD;
      Histopathological confirmed invasive breast tumors with no involvement of skin will be&#xD;
      treated using DaRT seeds.&#xD;
&#xD;
      The primary effectiveness endpoint of the study is the tumor response to DaRT treatment&#xD;
      assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1) 9-11&#xD;
      weeks after DaRT seed insertion.&#xD;
&#xD;
      Safety will be assessed by the cumulative frequency, severity and causality of acute adverse&#xD;
      events related to the DaRT treatment of adverse events (AEs) observed including the follow-up&#xD;
      period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2019</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response to DaRT</measure>
    <time_frame>9-11 weeks post DaRT insertion.</time_frame>
    <description>Assessment of the rate of malignant breast tumors response using the Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Day 0 - 6 months (+/-14 days)</time_frame>
    <description>Assessment of the frequency, severity and causality of acute adverse events related to the DaRT treatment using the Common Terminology and Criteria for adverse events (CTCAE) version 5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in tumor volume.</measure>
    <time_frame>9-11 weeks after DaRT insertion.</time_frame>
    <description>Assessment of the reduction in tumor volume SUVmax based on CT/PET - CT measured tumor volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DaRT seeds placement</measure>
    <time_frame>Day of insertion.</time_frame>
    <description>Assessment of the DaRT seed placement by localization of the DaRT seed in the tumor using CT imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life: EORTC-QLQ-C30</measure>
    <time_frame>Day 0, 30, 70, 6 months (+/-14 days).</time_frame>
    <description>Assessment of patient reported health-related Quality of Life (QoL) outcomes after DaRT treatment, using QoL questionnaires EORTC-QLQ-C30. Scale range in score from 0 (best) to 100(worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>6 months (+/-14 days).</time_frame>
    <description>Time elapsed from response to disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological remissions.</measure>
    <time_frame>12 weeks after DaRT seed insertion.</time_frame>
    <description>Assessment of (complete) pathological remissions using histopathology examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abscopal effects.</measure>
    <time_frame>9-11 weeks after DaRT insertion.</time_frame>
    <description>Assessment of abscopal effects on existing distant metastases based on PET-CT measured tumor volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life: BR23</measure>
    <time_frame>Day 0, 30, 70, 6 months (+/-14 days).</time_frame>
    <description>Assessment of patient reported health-related Quality of Life (QoL) outcomes after DaRT treatment, using QoL questionnaires BR23. Scale range in score from 0 (best) to 100(worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abscopal effects</measure>
    <time_frame>9-11 weeks after DaRT insertion.</time_frame>
    <description>Assessment of abscopal effects on existing distant metastases based on PET-CT measured SUVmax decrease compared to the primary measurement (the baseline measurement).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Carcinoma</condition>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Invasive Breast Cancer</condition>
  <condition>Distant Metastases.Pathology</condition>
  <arm_group>
    <arm_group_label>DaRT Seeds</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)</intervention_name>
    <description>An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.</description>
    <arm_group_label>DaRT Seeds</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with histopathological confirmation of primary (or recurrent) invasive breast&#xD;
             carcinoma and distant metastatic disease at diagnosis.&#xD;
&#xD;
          -  Target tumor size ≤ 3.0 cm (T1-2b category);&#xD;
&#xD;
          -  Morphological type: invasive breast cancer&#xD;
&#xD;
          -  Luminal-type A (ER+, PR+, Her2/neu +1), HER+, luminal-type B (ER +/-, PR +/-,&#xD;
             Her2/neu+1), or Triple negative breast carcinoma&#xD;
&#xD;
          -  Measurable disease according to RECIST v1.1.&#xD;
&#xD;
          -  Subjects over 45 years old.&#xD;
&#xD;
          -  Subjects' ECOG Performance Status Scale is &lt; 2.&#xD;
&#xD;
          -  Subjects' life expectancy more than 6 months.&#xD;
&#xD;
          -  Platelet count ≥100,000/mm3.&#xD;
&#xD;
          -  International normalized ratio of prothrombin time ≤1.8.&#xD;
&#xD;
          -  Creatinine ≤1.9 mg/dL.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test.&#xD;
&#xD;
          -  Subjects are willing to sign an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  T4 category with skin involvement.&#xD;
&#xD;
          -  Regional lymph node metastases.&#xD;
&#xD;
          -  Ductal carcinoma in situ.&#xD;
&#xD;
          -  Inflammatory breast carcinoma.&#xD;
&#xD;
          -  Patients with pre-irradiation of the breast.&#xD;
&#xD;
          -  Acute infection disease.&#xD;
&#xD;
          -  The presence of HIV, RW, HbsAg, HCV in the acute stage.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Serious competing (somatic) diseases incompatible according to the researcher with&#xD;
             brachytherapy.&#xD;
&#xD;
          -  Mental illness.&#xD;
&#xD;
          -  Patients undergoing immunosuppressive and/or systemic corticosteroid treatment&#xD;
&#xD;
          -  Volunteers participating in another interventional study in the past 30 days which&#xD;
             might conflict with the endpoints of this study or the evaluation of response or&#xD;
             toxicity of DaRT.&#xD;
&#xD;
          -  High probability of protocol non-compliance (in opinion of investigator).&#xD;
&#xD;
          -  Patients with significant comorbidities that the treating physician deems may conflict&#xD;
             with the endpoints of the study (e.g., poorly controlled autoimmune diseases,&#xD;
             vasculitis, etc.)&#xD;
&#xD;
          -  Subjects not willing to sign an informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleksandr Obukhov</last_name>
    <role>Principal Investigator</role>
    <affiliation>A. Tsyb Medical Radiological Research Centre, (A. Tsyb MRRC), Obninsk, Russia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naama Barel</last_name>
    <phone>+972-3-618-24770</phone>
    <email>Naamab@alphatau.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aleksandr Obukhov, Dr.</last_name>
    <email>obuxov_al@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A. Tsyb Medical Radiological Research Center</name>
      <address>
        <city>Obninsk</city>
        <state>Kaluga Region</state>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandr Obukhov, MD</last_name>
      <phone>+9264837984</phone>
      <email>obuxov_al@mail.ru</email>
    </contact>
    <contact_backup>
      <last_name>Natalia B. Borysheva, PhD</last_name>
      <phone>+79109109899</phone>
      <email>borysheva@yandex.ru</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast carcinoma</keyword>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>Invasive breast cancer</keyword>
  <keyword>Alpha radiation</keyword>
  <keyword>Luminal A</keyword>
  <keyword>Luminal B</keyword>
  <keyword>Triple negative</keyword>
  <keyword>HER2</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Breast metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

